Newest first. 5.2k questions across 107 tags.
What I am working with: SURMOUNT-OSA · 50 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Stated plainly: FGP · Xi’an Mokemei Biotechnology. Both of these get recommended confidently by different people, which suggests neither is obviously right. My…
Numbers first: Tianjin · the United Kingdom. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
Numbers first: cagrilintide · PIONEER-4. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I would…
What I have: Tianjin · the United Kingdom. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
Details up front: cagrilintide · a C8 column · survodutide. I have used one of these for a while and I am considering switching, which requires a reason. What I care…
What I have: KP · Bachem Holding (Suzhou). I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
I have started asking labs for "the system suitability data" and getting back either silence, a shrug, or a screenshot of six retention times. I clearly do not know…
Conditions: ecnoglutide · PIONEER-1. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
Conditions: 10 mg · four weeks · constipation. This is one of those things that everyone repeats and nobody derives. This matters practically, not just academically,…
The case in front of me: 10 mg · 0.5 mL · 0.9% sodium chloride · a GLP-1 receptor agonist. I want to decide this in advance so that I am not deciding it under…
The method section is present, which is unusual enough that I want to make use of it. These are treated as interchangeable and I do not think they are. If both are…
Concretely: SURMOUNT-OSA · liraglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs…
Conditions: list of related substances · SSA. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
Concretely: semaglutide · a C4 column · survodutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know…
The case in front of me: 10 mg · 2.5 mL · 0.9% sodium chloride · mazdutide. I want to decide this in advance so that I am not deciding it under pressure later. Assume…
The particulars: tirzepatide · three weeks. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement…
The specifics, since they change the answer: 4 mg · ten weeks · reflux. I understand the observation; what I do not understand is the mechanism behind it. I have read…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I understand the observation; what I do not understand is the mechanism…
The specifics, since they change the answer: tirzepatide · three weeks · room temperature. I understand the observation; what I do not understand is the mechanism…
For reference: QYB · ecnoglutide. Something has gone wrong and I would like to know how badly before I decide what to do. Nothing else in the setup changed, which is…
The method section is present, which is unusual enough that I want to make use of it. I have read the primary source rather than the summary, which has left me with…
What I am working with: REDEFINE-1 · 4 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…
Stated plainly: ERP · peptide mapping. The units are where I keep going wrong, so please be explicit about them. I have sanity-checked the order of magnitude and it…